ClinicalTrials.gg
CompletedNCT03798054Lixilan-O-APUpdated Jul 19, 2022

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

A Phase 3 interventional study of Insulin glargine/Lixisenatide (HOE901/AVE0010) and Insulin glargine (HOE901) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 79 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
878
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
14th of 175
878 · median 253
Started
2019
with 5 others
Phase 3
60 of 176
1 open now
Registered
150th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment of the 175 interventional ones that give a count, is one of 6 that started in 2019, is one of 60 in phase 3, and was the 150th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objectives:

The co-primary objective of this study is:

  • To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) versus lixisenatide on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change.
  • To demonstrate the non-inferiority of iGlarLixi versus insulin glargine on glycemic control as assessed by HbA1c change.

Secondary Objectives:

  • To assess the effects of iGlarLixi in comparison with insulin glargine alone and lixisenatide alone.
  • To assess the safety in each treatment group.
Read the detailed description

The maximum study duration per patient will be approximately 31 weeks: an up-to 6-week screening and run-in period (with an up-to 2-week screening phase and a 4-week run-in phase), followed by a 24-week randomized treatment period and a 3-day post-treatment safety follow up period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the screening visit (V1), treated for at least 3 months prior to the screening visit (V1) with metformin alone or metformin and a second oral antidiabetic treatment that can be a sulfonylurea (SU), a glinide, an alpha-glucosidase inhibitor (alpha-GI), a dipeptidyl peptidase-4 (DPP-4) inhibitor or a sodium-glucose co transporter 2 (SGLT-2) inhibitor and who are not adequately controlled with this treatment.
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Age \< legal age of majority at the screening visit (V1).
  • (BMI) >40 kg/m² at screening.
  • A1c (HbA1c) at screening visit:
  • \<7.5% or >11% for patients previously treated with metformin alone;
  • \<7.0% or >10% for patients previously treated with metformin and a second oral antidiabetic treatment.
  • History of hypoglycemia unawareness.
  • History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening.
  • Use of oral or injectable glucose-lowering agents other than those stated in the inclusion criteria within 3 months prior to screening.
  • Previous treatment with insulin (except for short-term treatment due to intercurrent illness at the discretion of the Investigator) within 1 year prior to screening.
  • History of discontinuation of a previous treatment with glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) due to safety/tolerability reasons or lack of efficacy.
  • Use of systemic (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to screening.
  • Use of weight loss drugs within 3 months prior to screening.
  • Use of any drug other than specified in this protocol within 1 month or 5 half-lives, whichever is longer, prior to screening.
  • Within 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization.
  • Planned coronary, carotid, or peripheral artery revascularization procedures to be performed during the study period.
  • Known history of drug or alcohol abuse within 6 months prior to screening.
  • Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic blood pressure >180 mmHg or diastolic blood pressure >95 mmHg.
  • Laboratory findings at screening visit (V1):
  • Amylase and/or lipase >3 times the (ULN) laboratory range.
  • (ALT) or aspartate aminotransferase (AST) >3 ULN.
  • Total >1.5 ULN (except in case of Gilbert's syndrome).
  • Calcitonin ≥20 pg/mL (5.9 pmol/L).
  • \<10.5 g/dL and/or neutrophils \<1500/mm3 and/or \<100 000/mm3.
  • Positive urine pregnancy test in female of .
  • Patient who has a severe renal function impairment with an estimated (eGFR) \<30 mL/min/1.73m2 or end-stage renal disease.
  • History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy.
  • Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes).
  • Use of SU, glinide, alpha-GI, DPP-4 inhibitor, and SGLT-2 inhibitor after start of run-in (from V2 [Week -4]).
  • HbA1c at V4 (Week -1) : \<7.0% or >10%.
  • Fasting plasma glucose >250 mg/dL (13.9 mmol/L) at V4 (Week-1) (can be repeated once to confirm).
  • Metformin maximal tolerated dose \<1500 mg/day.
  • Amylase and/or lipase >3 ULN at V4 (Week-1).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
878 participants (actual)

Study arms

  • Experimental
    Soliqua (insulin glargine/lixisenatide)

    iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning on top of metformin for 24 weeks.

    Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010) · Drug: Metformin · Drug: SGLT2 inhibitor

  • Active comparator
    Lantus (insulin glargine)

    Insulin glargine will be self-administered subcutaneously once daily at any time of the day on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.

    Drug: Insulin glargine (HOE901) · Drug: Metformin · Drug: SGLT2 inhibitor

  • Active comparator
    Lyxumia (lixisenatide)

    Lixisenatide will be self-administered subcutaneously once daily according to the locally approved label on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.

    Drug: Lixisenatide (AVE0010) · Drug: Metformin · Drug: SGLT2 inhibitor

Interventions

  • DrugInsulin glargine/Lixisenatide (HOE901/AVE0010)

    Drug pages: Insulin Glargine · Lixisenatide

    Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Soliqua, iGlarLixi

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Lantus

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Lyxumia

  • Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change in glycated hemoglobin (HbA1c) from baseline to Week 24

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Change in postprandial plasma glucose (PPG)

    Absolute change in 2-hour blood glucose excursion and PPG during meal test from baseline to Week 24 (for all patients in iGlarLixi or insulin glargine group and patients who receive morning injection in the lixisenatide group)

    Time frame: From Baseline to Week 24

  2. Change in fasting plasma glucose (FPG)

    Absolute change in FPG from baseline to Week 24

    Time frame: From Baseline to Week 24

  3. Change in self-monitored plasma glucose (SMPG) profile

    Absolute change in 7-point SMPG profiles from baseline to Week 24 (each time point and average daily value)

    Time frame: From Baseline to Week 24

  4. Patients with HbA1c <7.0%

    Percentage of patients reaching HbA1c \<7% at Week 24

    Time frame: At Week 24

  5. Patients with HbA1c ≤ 6.5%

    Percentage of patients reaching HbA1c ≤ 6.5% at Week 24

    Time frame: At Week 24

  6. Change in body weight

    Absolute change in body weight from baseline to Week 24

    Time frame: From Baseline to Week 24

  7. Patients with HbA1c <7.0% with no body weight gain

    Percentage of patients reaching HbA1c \<7% with no body weight gain at Week 24

    Time frame: At Week 24

  8. Patients with HbA1c <7.0% with no body weight gain and no documented symptomatic hypoglycemia

    Percentage of patients reaching HbA1c \<7% with no body weight gain at Week 24 and no documented (plasma glucose \[PG\] ≤70 mg/dL \[3.9 mmol/L\]) symptomatic hypoglycemia during the 24 week treatment period

    Time frame: At Week 24

  9. Confirmed hypoglycemia

    Including severe hypoglycemia and episodes of hypoglycemia documented with PG ≤70 mg/dL (3.9 mmol/L) regardless of symptoms from baseline to Week 24

    Time frame: From Baseline to Week 24

  10. Adverse events (AEs)

    Number of AEs, serious AEs, AEs of Special Interest, and AEs requiring specific monitoring from baseline to Week 24

    Time frame: From Baseline to Week 24

  11. Immunogenicity (antibody variables)

    Anti-lixisenatide antibodies and anti-insulin antibodies (depending on the treatment group) from baseline to Week 24

    Time frame: From Baseline to Week 24

07

Study locations

79 sites
  • Investigational Site Number 1560001
    Beijing, 1000029, China
  • Investigational Site Number 1560006
    Beijing, 101200, China
  • Investigational Site Number 1560049
    Beijing, 102218, China
  • Investigational Site Number 1560039
    Cangzhou, 061000, China
  • Investigational Site Number 1560009
    Changchun, 130033, China
  • Investigational Site Number 1560027
    Changchun, 130041, China
  • Investigational Site Number 1560016
    Changsha, 410013, China
  • Investigational Site Number 1560053
    Chengdu, 610081, China
  • Investigational Site Number 1560056
    Chengdu, 611130, China
  • Investigational Site Number 1560010
    Chenzhou, China
  • Investigational Site Number 1560037
    Chongqing, 400010, China
  • Investigational Site Number 1560050
    Chongqing, 400013, China
  • Investigational Site Number 1560044
    Dongguan, China
  • Investigational Site Number 1560033
    Guangzhou, 510120, China
  • Investigational Site Number 1560028
    Guangzhou, China
  • Investigational Site Number 1560012
    Handan, 056002, China
  • Investigational Site Number 1560023
    Hangzhou, China
  • Investigational Site Number 1560035
    Harbin, 150001, China
  • Investigational Site Number 1560036
    Harbin, 150001, China
  • Investigational Site Number 1560011
    Hengshui, 053000, China
  • Investigational Site Number 1560024
    Hohhot, 010017, China
  • Investigational Site Number 1560047
    Hohhot, 010050, China
  • Investigational Site Number 3440001
    Hong Kong, China
  • Investigational Site Number 1560025
    Huang Shi, China
  • Investigational Site Number 1560026
    Huanggang, China
  • Investigational Site Number 1560048
    Huizhou, 516001, China
  • Investigational Site Number 1560034
    Huzhou, China
  • Investigational Site Number 1560005
    Jinan, 250013, China
  • Investigational Site Number 1560052
    Jinhua, 321000, China
  • Investigational Site Number 1560031
    Jinzhou, 121000, China
  • Investigational Site Number 1560022
    Nanjing, 210029, China
  • Investigational Site Number 1560014
    Nanjing, China
  • Investigational Site Number 1560043
    Nanjing, China
  • Investigational Site Number 1560041
    Nanning, 530021, China
  • Investigational Site Number 1560032
    Qingdao, 266042, China
  • Investigational Site Number 1560038
    Qinhuangdao, China
  • Investigational Site Number 1560013
    Shanghai, 200072, China
  • Investigational Site Number 1560007
    Shanghai, 200240, China
  • Investigational Site Number 1560004
    Shanghai, 201700, China
  • Investigational Site Number 1560029
    Shanghai, China
  • Investigational Site Number 1560003
    Shenyang, 110022, China
  • Investigational Site Number 1560054
    Shenzhen, 518000, China
  • Investigational Site Number 1560019
    Suzhou, 215006, China
  • Investigational Site Number 1560059
    Suzhou, China
  • Investigational Site Number 1560021
    Tianjin, 300052, China
  • Investigational Site Number 1560017
    Tianjin, 300121, China
  • Investigational Site Number 1560058
    Urumqi, 830000, China
  • Investigational Site Number 1560018
    Wuhan, 430014, China
  • Investigational Site Number 1560008
    Xi'An, 710061, China
  • Investigational Site Number 1560055
    Xi'An, China
  • Investigational Site Number 1560051
    Xingtai, 054031, China
  • Investigational Site Number 1560030
    Xining, 810007, China
  • Investigational Site Number 1560040
    Yanji, 133000, China
  • Investigational Site Number 1560060
    Yueyang, 414000, China
  • Investigational Site Number 1560046
    Yueyang, China
  • Investigational Site Number 1560045
    Zhengzhou, China
  • Investigational Site Number 1560002
    Zhenjiang, 212001, China
  • Investigational Site Number 1560015
    Zhuzhou, 412007, China
  • Investigational Site Number 1560057
    Zigong, 643002, China
  • Investigational Site Number 4100009
    Ansan-Si, 15355, Korea, Republic of
  • Investigational Site Number 4100012
    Busan, 49241, Korea, Republic of
  • Investigational Site Number 4100010
    Guri-Si, Gyeonggi-Do, 11923, Korea, Republic of
  • Investigational Site Number 4100004
    Gwangju, 61469, Korea, Republic of
  • Investigational Site Number 4100003
    Seongnam-Si, 13620, Korea, Republic of
  • Investigational Site Number 4100016
    Seoul, 01832, Korea, Republic of
  • Investigational Site Number 4100011
    Seoul, 03181, Korea, Republic of
  • Investigational Site Number 4100013
    Seoul, 03722, Korea, Republic of
  • Investigational Site Number 4100001
    Seoul, 05278, Korea, Republic of
  • Investigational Site Number 4100002
    Seoul, 08308, Korea, Republic of
  • Investigational Site Number 4100005
    Wonju, 26426, Korea, Republic of
  • Investigational Site Number 4580001
    Kelantan, 16150, Malaysia
  • Investigational Site Number 4580005
    Kuala Lumpur, 56000, Malaysia
  • Investigational Site Number 4580003
    Kuala Lumpur, 59100, Malaysia
  • Investigational Site Number 4580006
    Kuching, 93586, Malaysia
  • Investigational Site Number 4580002
    Putrajaya, Malaysia
  • Investigational Site Number 4580004
    Seremban, 70300, Malaysia
  • Investigational Site Number 1580003
    Taichung, 407, Taiwan
  • Investigational Site Number 1580005
    Tainan Hsien, 710, Taiwan
  • Investigational Site Number 1580004
    Taipei, 11031, Taiwan
08

References and documents

Publications

  • Yang W, Dong X, Li Q, Cheng Z, Yuan G, Liu M, Xiao J, Gu S, Niemoeller E, Chen L, Ping L, Souhami E; LixiLan-O-AP trial investigators. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. Diabetes Obes Metab. 2022 Aug;24(8):1522-1533. doi: 10.1111/dom.14722. Epub 2022 May 12. PubMed 35441412 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Mar 2021, 24 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2019
First posted
Jan 9, 2019
StartActual
Feb 15, 2019
Primary completionActual
Mar 1, 2021
CompletionActual
Mar 1, 2021
Last update
Jul 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03798054
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 9, 2019
Start date
Feb 15, 2019
Primary completion
Mar 1, 2021
Completion
Mar 1, 2021
Last update
Jul 19, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Lixisenatide

Start the discussion